AMZN,Amazon Indians report more death threats after activists slainGerman union launches new strike at Amazon warehousesAmazon to use bike messengers for one-hour delivery in New York City-WSJ Dec 8 E-commerce giant Amazon.com Inc  plans to experiment with bike messengers to offer deliveries in New York City within an hour, the Wall Street Journal reported, citing a source familiar with the matter.  Amazon to use bike messengers for one-hour delivery in New York City-WSJ Dec 8 E-commerce giant Amazon.com Inc  plans to experiment with bike messengers to offer deliveries in New York City within an hour, the Wall Street Journal reported, citing a source familiar with the matter. BERLIN Workers at two of Amazon.com's  German warehouses went on strike on Monday as labor union Verdi sought to squeeze the online retailer in the busy pre-Christmas period in a long-running dispute over pay and conditions.Amazon to use bike messengers for one-hour delivery in New York City-WSJ Dec 8 E-commerce giant Amazon.com Inc  plans to experiment with bike messengers to offer deliveries in New York City within an hour, the Wall Street Journal reported, citing a source familiar with the matter.   German union launches new strike at Amazon warehousesAmazon to use bike messengers for one-hour delivery in New York City-WSJ Dec 8 E-commerce giant Amazon.com Inc  plans to experiment with bike messengers to offer deliveries in New York City within an hour, the Wall Street Journal reported, citing a source familiar with the matter.  Amazon to use bike messengers for one-hour delivery in New York City-WSJ Dec 8 E-commerce giant Amazon.com Inc  plans to experiment with bike messengers to offer deliveries in New York City within an hour, the Wall Street Journal reported, citing a source familiar with the matter. BERLIN Workers at two of Amazon.com's  German warehouses went on strike on Monday as labor union Verdi sought to squeeze the online retailer in the busy pre-Christmas period in a long-running dispute over pay and conditions.Amazon to use bike messengers for one-hour delivery in New York City-WSJ Dec 8 E-commerce giant Amazon.com Inc  plans to experiment with bike messengers to offer deliveries in New York City within an hour, the Wall Street Journal reported, citing a source familiar with the matter.  LIMA/SAO PAULO (Thomson Reuters Foundation) - Indians on the Peru-Brazil border say they continue to receive death threats from loggers after the murder of four local chiefs in a remote forest region overrun by illegal felling.German union launches new strike at Amazon warehousesAmazon to use bike messengers for one-hour delivery in New York City-WSJ Dec 8 E-commerce giant Amazon.com Inc  plans to experiment with bike messengers to offer deliveries in New York City within an hour, the Wall Street Journal reported, citing a source familiar with the matter.  Amazon to use bike messengers for one-hour delivery in New York City-WSJ Dec 8 E-commerce giant Amazon.com Inc  plans to experiment with bike messengers to offer deliveries in New York City within an hour, the Wall Street Journal reported, citing a source familiar with the matter. BERLIN Workers at two of Amazon.com's  German warehouses went on strike on Monday as labor union Verdi sought to squeeze the online retailer in the busy pre-Christmas period in a long-running dispute over pay and conditions.Amazon to use bike messengers for one-hour delivery in New York City-WSJ Dec 8 E-commerce giant Amazon.com Inc  plans to experiment with bike messengers to offer deliveries in New York City within an hour, the Wall Street Journal reported, citing a source familiar with the matter.   
AAL,American Airlines' Envoy Air in tentative agreement with pilotsUPDATE 1-American Airlines' Envoy unit in tentative agreement with pilots Dec 8 American Airlines Group Inc  subsidiary Envoy Air has reached a tentative agreement with its pilots, according to an internal letter from Sunday reviewed by Reuters.  UPDATE 1-American Airlines' Envoy unit in tentative agreement with pilots Dec 8 American Airlines Group Inc  subsidiary Envoy Air has reached a tentative agreement with its pilots, according to an internal letter from Sunday reviewed by Reuters. Dec 8 American Airlines subsidiary Envoy Air has reached a tentative agreement with its pilots, according to an internal letter from Sunday reviewed by Reuters.UPDATE 1-American Airlines' Envoy unit in tentative agreement with pilots Dec 8 American Airlines Group Inc  subsidiary Envoy Air has reached a tentative agreement with its pilots, according to an internal letter from Sunday reviewed by Reuters.  
AAPL,Chinese Internet regulator welcomed at Facebook campus BEIJING Lu Wei, China's top Internet regulator, may not welcome Facebook to his house, but he's certainly welcome at Facebook. 
C,MOVES-Citigroup's EMEA DCM head Young leaves for Mitsubishi LONDON, Dec 8 (IFR) - LONDON, Dec 8 (IFR)- Paul Young, Citigroup's head of debt capital markets for Europe, Middle East and Africa, has left the bank, according to one person with knowledge of the situation. 
COP,ConocoPhillips plans to spend less in 2015 amid steep crude fallUPDATE 3-ConocoPhillips plans to spend less in 2015 as crude slides * To cut investment on less developed shales in N. America  UPDATE 3-ConocoPhillips plans to spend less in 2015 as crude slides * To cut investment on less developed shales in N. America Dec 8 ConocoPhillips set a capital budget of $13.5 billion for 2015, a 20 percent drop from its 2014 spending plans, amid a steep decline in global crude prices.UPDATE 3-ConocoPhillips plans to spend less in 2015 as crude slides * To cut investment on less developed shales in N. America  
FB,Chinese Internet regulator welcomed at Facebook campus BEIJING, Dec 8 Lu Wei, China's top Internet regulator, may not welcome Facebook to his house, but he's certainly welcome at Facebook. 
BEN,Franklin Income Fund hit by oil slump, but sees opportunity BOSTON, Dec 8 The Franklin Income Fund  is used to top-dog status among its mutual fund peers, but a 40 percent slide in oil prices since June has hammered its recent performance. 
GM,Two more deaths eligible for General Motors compensation WASHINGTON, Dec 8 Claims deemed eligible for compensation from a faulty ignition switch in General Motors Co  vehicles rose slightly in the last week, including two additional deaths attributed to the defective switch, according to an official report on Monday. 
GS,Obamacare helps private equity get its rehab clinic fixRBS launches sale of Coutts, invites bids before Christmas: sources SINGAPORE/HONG KONG Royal Bank of Scotland Plc  has launched the sale of private bank Coutts International and has invited at least 10 potential suitors, including Credit Suisse , Julius Baer  and Malayan Banking Bhd  to participate in an auction, sources said.  RBS launches sale of Coutts, invites bids before Christmas: sources SINGAPORE/HONG KONG Royal Bank of Scotland Plc  has launched the sale of private bank Coutts International and has invited at least 10 potential suitors, including Credit Suisse , Julius Baer  and Malayan Banking Bhd  to participate in an auction, sources said. Investors are pouring money into the operators of U.S. rehab centers as many more Americans get health care coverage for addiction treatment, driving up valuations and triggering a consolidation of businesses in the fragmented sector.RBS launches sale of Coutts, invites bids before Christmas: sources SINGAPORE/HONG KONG Royal Bank of Scotland Plc  has launched the sale of private bank Coutts International and has invited at least 10 potential suitors, including Credit Suisse , Julius Baer  and Malayan Banking Bhd  to participate in an auction, sources said.  
MCD,US STOCKS-Futures lower after China, Japan data disappointsUS STOCKS-Wall St to open lower after Japan, China dataUS STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)       US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)        US STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)       US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)       * Futures down: Dow 58 pts, S&P; 7 pts, Nasdaq 15.25 pts   (Adds quote, updates prices)US STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)       US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)         US STOCKS-Wall St to open lower after Japan, China dataUS STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)       US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)        US STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)       US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)       * Futures down: Dow 58 pts, S&P; 7 pts, Nasdaq 15.25 pts   (Adds quote, updates prices)US STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)       US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)        * Futures down: Dow 56 pts, S&P; 6.75 pts, Nasdaq 12.5 pts   (Adds premarket actives data)US STOCKS-Wall St to open lower after Japan, China dataUS STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)       US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)        US STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)       US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)       * Futures down: Dow 58 pts, S&P; 7 pts, Nasdaq 15.25 pts   (Adds quote, updates prices)US STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)       US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbUS STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)      US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)US STOCKS-Wall St falls with energy shares; global data disappointsCORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)     CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    * Indexes: Dow off 0.5 pct, S&P; 0.6 pct, Nasdaq down 0.8 pct   (Updates to early afternoon)CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, CelgeneUS STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)    US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)US STOCKS-Wall St drops with energy shares; global data disappointsUPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)   UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  * Indexes: Dow off 0.7 pct, S&P; 0.8 pct, Nasdaq down 1 pct   (Updates to early afternoon trading)UPDATE 3-McDonald's warns that weak sales will hit Q4 profitUS STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)  US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close) Dec 8 McDonald's Corp on Monday reported a steeper-than-expected drop in global sales at established restaurants for November, hurt by weakness in the United States and Asia, and warned that such declines would "significantly pressure" margins this quarter.US STOCKS-S&P; 500 posts worst day since Oct; energy shares sink * Indexes: Dow off 0.6 pct, S&P; 0.7 pct, Nasdaq down 0.8 pct   (Updates to close)         
MRK,US STOCKS-Futures lower after China, Japan data disappointsUS STOCKS-Wall St to open lower after Japan, China dataUS STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.       US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.        US STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.       US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.       * Futures down: Dow 58 pts, S&P; 7 pts, Nasdaq 15.25 pts   (Adds quote, updates prices)US STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.       US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.         US STOCKS-Wall St to open lower after Japan, China dataUS STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.       US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.        US STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.       US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.       * Futures down: Dow 58 pts, S&P; 7 pts, Nasdaq 15.25 pts   (Adds quote, updates prices)US STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.       US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.        * Futures down: Dow 56 pts, S&P; 6.75 pts, Nasdaq 12.5 pts   (Adds premarket actives data)US STOCKS-Wall St to open lower after Japan, China dataUS STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.       US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.        US STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.       US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.       * Futures down: Dow 58 pts, S&P; 7 pts, Nasdaq 15.25 pts   (Adds quote, updates prices)US STOCKS-Wall St slips after Japan, China data; energy dragsUS STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.       US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      * Indexes down: Dow 0.12 pct, S&P; 0.11 pct, Nasdaq 0.12 pct   (Updates to market open)US STOCKS-Wall St flat after Japan, China data; biotechs climbCubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.      Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     * Indexes: Dow off 0.06 pct, S&P; 0.05 pct, Nasdaq up 0.17 pct   (Updates to late morning)Cubist options unusually active before Merck dealCubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.     Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    NEW YORK, Dec 8 Cubist Pharmaceuticals Inc  options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co  will buy Cubist for a hefty premium.Cubist options unusually active before Merck dealBreakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.    Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   NEW YORK Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck & Co will buy Cubist for a hefty premium.Breakingviews: Merck bets $8.4 bln on more profitable antibioticsUPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.   UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  NEW YORK (Reuters Breakingviews) - Superbugs may have beneficial side effects - for giant pharmaceutical companies. In agreeing to buy Cubist Pharmaceuticals, Merck  is betting $8.4 billion that the antibiotics used to fight them will become more profitable.UPDATE 4-Merck to take on superbugs with Cubist Pharma buyMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.  Merck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs. * Merck to pay $8.4 bln, plus assumption of $1.1 bln of debtMerck to take on superbugs with Cubist Pharma buy Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.         
PFE,Pfizer bets on gene therapy as technology comes of age LONDON, Dec 8 Pfizer Inc is moving into the gene therapy space in the latest sign that the technology for fixing faulty genes may finally be ready for prime time, following earlier setbacks. 
SYK,Stryker pleads guilty to selling unapproved devices, to pay $80 mlnUPDATE 1-Stryker pleads guilty to selling unapproved devices, to pay $80 mlnStryker pleads guilty to selling unapproved devices, to pay $80 million Medical device maker Stryker Corp will pay the U.S. government $80 million to settle criminal and civil charges that its OtisMed Corp subsidiary sold devices used in knee replacement surgery without approval from the U.S. Food and Drug Administration.  Stryker pleads guilty to selling unapproved devices, to pay $80 million Medical device maker Stryker Corp will pay the U.S. government $80 million to settle criminal and civil charges that its OtisMed Corp subsidiary sold devices used in knee replacement surgery without approval from the U.S. Food and Drug Administration. (Recasts lead with charges being both criminal and civil )Stryker pleads guilty to selling unapproved devices, to pay $80 million Medical device maker Stryker Corp will pay the U.S. government $80 million to settle criminal and civil charges that its OtisMed Corp subsidiary sold devices used in knee replacement surgery without approval from the U.S. Food and Drug Administration.   UPDATE 1-Stryker pleads guilty to selling unapproved devices, to pay $80 mlnStryker pleads guilty to selling unapproved devices, to pay $80 million Medical device maker Stryker Corp will pay the U.S. government $80 million to settle criminal and civil charges that its OtisMed Corp subsidiary sold devices used in knee replacement surgery without approval from the U.S. Food and Drug Administration.  Stryker pleads guilty to selling unapproved devices, to pay $80 million Medical device maker Stryker Corp will pay the U.S. government $80 million to settle criminal and civil charges that its OtisMed Corp subsidiary sold devices used in knee replacement surgery without approval from the U.S. Food and Drug Administration. (Recasts lead with charges being both criminal and civil )Stryker pleads guilty to selling unapproved devices, to pay $80 million Medical device maker Stryker Corp will pay the U.S. government $80 million to settle criminal and civil charges that its OtisMed Corp subsidiary sold devices used in knee replacement surgery without approval from the U.S. Food and Drug Administration.  Dec 8 Medical device maker Stryker Corp  will pay the U.S. government $80 million to settle charges that its OtisMed Corp subsidiary sold devices used in knee replacement surgery without approval from the U.S. Food and Drug Administration.UPDATE 1-Stryker pleads guilty to selling unapproved devices, to pay $80 mlnStryker pleads guilty to selling unapproved devices, to pay $80 million Medical device maker Stryker Corp will pay the U.S. government $80 million to settle criminal and civil charges that its OtisMed Corp subsidiary sold devices used in knee replacement surgery without approval from the U.S. Food and Drug Administration.  Stryker pleads guilty to selling unapproved devices, to pay $80 million Medical device maker Stryker Corp will pay the U.S. government $80 million to settle criminal and civil charges that its OtisMed Corp subsidiary sold devices used in knee replacement surgery without approval from the U.S. Food and Drug Administration. (Recasts lead with charges being both criminal and civil )Stryker pleads guilty to selling unapproved devices, to pay $80 million Medical device maker Stryker Corp will pay the U.S. government $80 million to settle criminal and civil charges that its OtisMed Corp subsidiary sold devices used in knee replacement surgery without approval from the U.S. Food and Drug Administration.   
UTX,UTC chairman says voiced concern about ex-CEO's priorities before departureUTC chairman says voiced concern about ex-CEO's priorities before departurePratt & Whitney Canada says to spend over C$1 billion on R&D;RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.  RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines. TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.   Pratt & Whitney Canada says to spend over C$1 billion on R&D;RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.  RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines. TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.  United Technologies Corp's new chairman, Edward Kangas, said former chief executive Louis Chenevert stepped down late last month after Kangas spoke to him out of concern about his priorities.Pratt & Whitney Canada says to spend over C$1 billion on R&D;RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.  RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines. TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.    UTC chairman says voiced concern about ex-CEO's priorities before departurePratt & Whitney Canada says to spend over C$1 billion on R&D;RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.  RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines. TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.   Pratt & Whitney Canada says to spend over C$1 billion on R&D;RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.  RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines. TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.  United Technologies Corp's new chairman, Edward Kangas, said former chief executive Louis Chenevert stepped down late last month after Kangas spoke to him out of concern about his priorities.Pratt & Whitney Canada says to spend over C$1 billion on R&D;RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.  RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines. TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.   Dec 7 United Technologies Corp's new chairman, Edward Kangas, said former chief executive Louis Chenevert stepped down late last month after Kangas spoke to him out of concern about his priorities.UTC chairman says voiced concern about ex-CEO's priorities before departurePratt & Whitney Canada says to spend over C$1 billion on R&D;RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.  RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines. TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.   Pratt & Whitney Canada says to spend over C$1 billion on R&D;RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.  RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines. TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.  United Technologies Corp's new chairman, Edward Kangas, said former chief executive Louis Chenevert stepped down late last month after Kangas spoke to him out of concern about his priorities.Pratt & Whitney Canada says to spend over C$1 billion on R&D;RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.  RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines. TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.RPT-Pratt & Whitney Canada says to spend over C$1 billion on R&D; TORONTO, Dec 8 United Technologies Corp  unit Pratt & Whitney Canada said on Monday it will invest more than C$1 billion ($874 million) over 4-1/2 years to develop new high-performance plane engines.    
V,UK consumer spending rises as "Black Friday" crosses Atlantic - Visa LONDON, Dec 8 British consumer spending grew strongly in November after many big retailers adopted U.S.-style "Black Friday" promotions, payments company Visa Europe said on Monday, suggesting spending for 2014 as a whole may rise at its fastest rate since 2010. 
WFC,Homeowners, Wells Fargo head to trial over mortgage feesDIARY-U.S. MEETINGS/WEEK AHEADRPT-Homeowners, Wells Fargo head to trial over mortgage feesHomeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.  Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp. NEW YORK, Dec 8 Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.   RPT-Homeowners, Wells Fargo head to trial over mortgage feesHomeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.  Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp. NEW YORK, Dec 8 Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.  Thomson Reuters Dec 8, 2014 - Corporate Meetings for US companies for Week ahead.         S&P; 500 Earnings - MONTH AHEAD     Dividends                            Non S&P; 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC, right click, now click on Related Co Data, now click on Co Events.                   RPT-Homeowners, Wells Fargo head to trial over mortgage feesHomeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.  Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp. NEW YORK, Dec 8 Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.    DIARY-U.S. MEETINGS/WEEK AHEADRPT-Homeowners, Wells Fargo head to trial over mortgage feesHomeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.  Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp. NEW YORK, Dec 8 Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.   RPT-Homeowners, Wells Fargo head to trial over mortgage feesHomeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.  Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp. NEW YORK, Dec 8 Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.  Thomson Reuters Dec 8, 2014 - Corporate Meetings for US companies for Week ahead.         S&P; 500 Earnings - MONTH AHEAD     Dividends                            Non S&P; 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC, right click, now click on Related Co Data, now click on Co Events.                   RPT-Homeowners, Wells Fargo head to trial over mortgage feesHomeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.  Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp. NEW YORK, Dec 8 Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.   NEW YORK Wells Fargo & Co,  the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.DIARY-U.S. MEETINGS/WEEK AHEADRPT-Homeowners, Wells Fargo head to trial over mortgage feesHomeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.  Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp. NEW YORK, Dec 8 Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.   RPT-Homeowners, Wells Fargo head to trial over mortgage feesHomeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.  Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp. NEW YORK, Dec 8 Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.  Thomson Reuters Dec 8, 2014 - Corporate Meetings for US companies for Week ahead.         S&P; 500 Earnings - MONTH AHEAD     Dividends                            Non S&P; 500 - Weekly             Federal Reserve events               ConferenceCall/Webcast - Weekly  Meetings - Weekly                                Xtra users can see more details on conference calls & webcasts by hovering your mouse  over the RIC, right click, now click on Related Co Data, now click on Co Events.                   RPT-Homeowners, Wells Fargo head to trial over mortgage feesHomeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.  Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp. NEW YORK, Dec 8 Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.Homeowners, Wells Fargo head to trial over mortgage fees NEW YORK Wells Fargo & Co, the largest U.S. mortgage lender, is set to go to trial on Monday as homeowners seek to recoup about $629 million for alleged overcharges by a company once owned by Wachovia Corp.    
